RECENT FUNDING ROUNDS
| Company | Country | Profile | Funding round | Value | Date | |
|---|---|---|---|---|---|---|
|
Neurelis Inc | Neuroscience company. | Series D | USD 114,000,000 | ||
|
Maridose LLC | Biotech - Cannabis R&D. We are a US DEA licensed manufacturer of Schedule 1 drugs. | Pre Seed | USD 150,000 | ||
|
Gilgamesh Pharmaceuticals Inc | Novel psychedelic-Inspired therapeutics for treating mental illness. | Seed | |||
|
3-V Biosciences Inc | Biopharmaceutical company discovering and developing novel therapeutics for the treatment of infectious diseases. | Series B | USD 30,000,000 | ||
|
Vyome Biosciences Pvt Ltd | Developer of medicines for treating skin diseases caused by resistant microbes. | Series C | USD 14,000,000 | ||
|
Arcis Biotechnology Holdings Ltd | N/A | GBP 2,500,000 | |||
|
FunkSac LLC | Provider of customer services and compliant packaging solutions for the legal cannabis industry; both medical and recreational markets. | N/A | |||
|
23andMe Inc | DNA testing and genome sequencing firm. | Series E | USD 79,100,000 | ||
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
3SBio Inc | IPO | HKD 5,510,000,000 | |||
|
|
Avanir Pharmaceuticals Inc | A biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. | Acquisition | USD 3,500,000,000 | ||
|
|
Omega Pharma Belgium NV | Belgian pharmaceutical company manufacturing and marketing a wide range of over-the-counter products in 35 countries worldwide. | Acquisition | USD 4,500,000,000 | ||
|
|
InterMune Inc | Biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. | Acquisition | USD 8,300,000,000 | ||
|
|
23andMe Inc | DNA testing and genome sequencing firm. | Grant | USD 1,400,000 | ||
|
|
ViroPharma Inc | Provider of life-saving medicines for life-threatening diseases. | Acquisition | USD 495,000,000 | ||
|
Merck & Co | Acquisition | USD 14,200,000,000 | |||
|
|
Arecor Ltd | Developer of technology that is used in the formulation of biopharmaceuticals. | N/A | |||
|
|
ViroPharma Inc | Provider of life-saving medicines for life-threatening diseases. | Acquisition | USD 4,200,000,000 | ||
|
|
Zosano Pharma Inc | Debt | USD 3,030,000 | |||
|
|
3-V Biosciences Inc | Biopharmaceutical company discovering and developing novel therapeutics for the treatment of infectious diseases. | Series C | USD 20,000,000 | ||
|
|
Warner Chilcott Corp | Acquisition | USD 8,500,000,000 |
MOST ACTIVE INVESTORS
MOST ACTIVE ACQURERS
| Pfizer Inc | US | 6 |
| Abbott Laboratories | US | 3 |
| Ampersand Ventures | US | 3 |
| Gilead Sciences Inc | US | 3 |
| Biogen Idec Inc | US | 1 |
| Serologicals Corp | US | 1 |
| Corixa Corp | US | 1 |
| Pharmion Corp | US | 1 |
| GelTex Pharmaceuticals | US | 1 |
| Otsuka Pharmaceutical | 1 | |
| Shire PLC | 1 | |
| GlaxoSmithKline | 1 | |
| Takeda Pharmaceutical Co Ltd | 1 | |
| Johnson & Johnson Innovation LLC | US | 1 |
| Allscripts Healthcare Solutions Inc | US | 1 |
| Perrigo | 1 | |
| Emerging Capital Partners | US | 1 |
| Viatris | 1 | |
| Bayer AG | DE | 1 |
| Actavis PLC | US | 1 |
| F Hoffmann-La Roche Ltd | 1 | |
| Vets First Choice | 1 | |
| Baxter International Inc | US | 1 |
| Roche Holding AG | 1 | |
| Cubist Pharmaceuticals Inc | 1 | |
| Hologic Inc | US | 1 |
| Biovitrum AB | SE | 1 |
| Genzyme Corp | US | 1 |
| Galapagos NV | BE | 1 |
| Aquila Biopharmaceuticals Inc | 1 |
BEST FUNDED STARTUPS
![[current-page:title] logo](/sites/default/files/styles/thumbnail/public/default_images/_no-logo.png?itok=xgKd-YA_){kind=logo}
Biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.
Belgian pharmaceutical company manufacturing and marketing a wide range of over-the-counter products in 35 countries worldwide.
A biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need.
Biopharmaceutical company discovering and developing novel therapeutics for the treatment of infectious diseases.
Novel small molecule, receptor-specific therapeutics company for the treatment of central nervous system, cardiovascular and renal diseases.
Advanced fight against drug resistant microbes by attacking novel targets with novel drugs.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases.
Developer of small molecule therapeutics for the treatment of inflammatory disease
Developer of products that penetrate the mucosal barrier to treat a variety of severe diseases